CONMED (US:CNMD) ZACKS·2026-02-27 17:30Core Viewpoint - CONMED Corporation has shown a positive performance with a 22.9% increase in shares since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Financial Performance - Adjusted earnings per share (EPS) for Q4 2025 was $1.43, a 6.7% increase year over year, while GAAP EPS was 54 cents, down 50% from $1.08 in the previous year [2] - Total revenues for Q4 were $373.2 million, reflecting a 7.9% year-over-year increase, and full-year revenues reached $1.37 billion, up 5.2% from the previous year [3] Segment Performance - Orthopedic Surgery revenues in Q4 totaled $157.4 million, up 13.2% year over year, while General Surgery revenues were $215.8 million, up 4.3% [4] - U.S. General Surgery sales declined by 0.4%, but international sales increased by 16.3% [5] Geographical Results - Domestic revenues in Q4 were $206.2 million, up 1.4% year over year, while international revenues were $167 million, up 17% [6] Margin Analysis - Gross profit increased by 10.1% year over year to $218.3 million, with a gross margin of 58.5%, while total operating profit fell by 30.2% to $36.6 million [8][9] Financial Position - Cumulative net cash provided by operating activities at the end of Q4 2025 was $170.7 million, compared to $166.9 million a year ago [10] Guidance - For 2026, total reported revenues are expected to be between $1,345 million and $1,375 million, with adjusted EPS projected in the range of $4.30 to $4.45 [11] Estimate Trends - Since the earnings release, there has been a downward trend in estimates, with a consensus estimate shift of -11.71% [12] VGM Scores - CONMED has an average Growth Score of C, a Momentum Score of D, and a Value Score of A, resulting in an aggregate VGM Score of B [13] Outlook - Estimates for the stock have been trending downward, indicating a potential in-line return in the coming months, with a Zacks Rank of 3 (Hold) [14]